Phospho-CCNB1(S126) Antibody Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P14635 |
---|---|
Clone Names | 5021453 |
Peptide ID | 5021453 |
Gene ID | 891 |
---|---|
Other Names | G2/mitotic-specific cyclin-B1, CCNB1, CCNB |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP3078a was selected from the 119-133 |
Format | The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CCNB1 |
---|---|
Synonyms | CCNB |
Function | Essential for the control of the cell cycle at the G2/M (mitosis) transition. |
Cellular Location | Cytoplasm. Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abgent.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a regulatory protein involved in mitosis. The gene product complexes with p34(cdc2) to form the maturation-promoting factor (MPF). Two alternative transcripts have been found, a constitutively expressed transcript and a cell cycle-regulated transcript, that is expressed predominantly during G2/M phase. The different transcripts result from the use of alternate transcription initiation sites.
References
Yoshida, T., et al., Ann. Oncol. 15(2):252-256 (2004).Chang, D.C., et al., J. Biol. Chem. 278(39):37865-37873 (2003).Sanchez, V., et al., J. Virol. 77(24):13214-13224 (2003).Li, J.Q., et al., Int. J. Oncol. 22(5):1101-1110 (2003).Porter, L.A., et al., Blood 101(5):1928-1933 (2003).

If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.